AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 231 min read$MED

MED Q3'26 Earnings: EPS estimate is (0.35) USD

Medifast (MED) will report Q3 2026 earnings on October 26. Analysts expect revenue of $71.3M and a loss of $0.35 per share, according to estimates.

Original reporting
tradingview.com
Published Oct 23, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
MED Q3'26 Earnings: EPS estimate is (0.35) USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$MEDBearishMed
01

Why it matters

The negative EPS estimate signals possible downside, but the actual impact will depend on whether the final results beat or miss the guidance.

02

Market read

Earnings preview provides actionable insight for traders ahead of the Oct 26 release.

03

What to watch

Potential cost‑cutting measures or product launches not mentioned in the brief.

Relevance 6/10Novelty 6/10Timing: post‑market release on Oct 26

Background

MEDIFAST INC is a U.S. health‑and‑wellness company that reports quarterly results.

Company-level read

Ticker impact

$MEDBearishHigh confidence
Context

MED announced its Q3'26 earnings estimate of (0.35) USD EPS and $71.3M revenue ahead of the Oct 26 release.

Expected impact

likely pressure as the market prices in the negative EPS guidance

Evidence & confidence

The disclosed EPS of (0.35) USD is below breakeven, suggesting downside risk when results are released.

Market effects

Sector

Weak guidance may pressure other small‑cap health‑and‑wellness stocks.

Regional

Limited to U.S. small‑cap segment.

Global

Low

Counterpoint

What could challenge this read

If the company exceeds the bleak estimate, a short‑cover rally could occur.

Key entities

  • company
    MEDIFAST INC

    U.S. listed health‑and‑wellness firm (ticker MED).

Read at source← All news

Related articles

OCT 28
$MEDMed

5 insightful analyst questions from Medifast’s Q3 earnings call

Medifast's Q3 revenue exceeded expectations but declined year-over-year. Management cited the Trilogy brand's success and improved coach productivity. Analysts questioned coach engagement, competition with GLP-1 medications, and cost reduction. The stock is trading at $12.50. Key focus areas include Trilogy adoption, coach productivity, and cost efficiencies.

financialcontent.com2 min
OCT 27
$MEDHigh

Why Medifast (MED) stock is trading up today

Medifast (MED) shares rose 6.2% after Q3 results beat expectations, with adjusted EBITDA of $1.9M. CEO Nick Johnson highlighted new product launches and guidance for Q4 revenue of $55M-$75M. Full-year revenue is expected at $280M-$300M, with a GAAP loss of $1.80-$2.05 per share.

financialcontent.com2 min
OCT 27
$MEDMed

Medifast Inc (MED) (Q3 2026) Earnings Call Highlights: Revenue Stabilizes Near $75 Million

Medifast Inc (MED) reported Q3 2026 revenue of $72M, down 19.4% YoY, with revenue stabilizing near $75M for four quarters. CEO Nicholas Johnson highlighted high engagement and productivity among coaches, despite a decline in active coach numbers. The company expects continued productivity growth and cost efficiencies. Q4 revenue guidance is $55M-$75M, with EPS of $0-$0.25. Medifast has $172.5M in cash and no debt, with a target of profitability in Q4 2026.

finance.yahoo.com2 min
OCT 26
$MEDMed

Medifast, Inc. Q3 2026 Earnings Call Summary

Medifast (MED) reported a 19.4% revenue decline in Q3 2026, attributing it to lower active coach counts due to GLP-1 medication adoption. The company is transitioning to a metabolic health system called Trilogy and implementing cost-cutting measures. Q4 2026 revenue is expected between $55M and $75M, with a focus on profitability and long-term growth. Management sees GLP-1s as a catalyst for consumer interest rather than a direct threat.

finance.yahoo.com2 min
OCT 26
$MEDMed

What Medifast (MED) Said on Its Q3 Earnings Call

Medifast (MED) reported a Q3 operating loss of $19.4M, including restructuring charges. The company introduced new products and highlighted GLP-1 medications' impact on client conversations. Medifast forecasts Q4 revenue of $55M-$75M and full-year 2026 revenue of $280M-$300M, aiming for profitability in Q4.

finance.yahoo.com2 min